Sign In
Buy SYRE
$97.05
-3.27 (-3.26%)
At Close: Jun 23, 2026
Spyre says bowel disease drug cuts inflammation in mid-stage trial
08:28am, Monday, 15'th Jun 2026
Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial.
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:58pm, Monday, 08'th Jun 2026
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Spyre Therapeutics Announces Grants of Inducement Awards
04:01pm, Friday, 05'th Jun 2026
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-genera
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
12:01pm, Thursday, 04'th Jun 2026
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
08:00am, Wednesday, 03'rd Jun 2026
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
04:10pm, Tuesday, 26'th May 2026
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Tuesday, 05'th May 2026
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Ann
Spyre Therapeutics Announces Grants of Inducement Awards
04:28pm, Friday, 01'st May 2026
WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies an
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
01:36pm, Thursday, 23'rd Apr 2026
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade
02:19am, Wednesday, 15'th Apr 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s share price gapped up before the market opened on Tuesday after Robert W. Baird raised their price target on the stock from $65.00 to $90.00
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
10:38pm, Tuesday, 14'th Apr 2026
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody e
Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
07:45am, Tuesday, 14'th Apr 2026
Spyre Therapeutics delivered strong Phase 2 data for SPY001, showing rapid, deep efficacy and a clean safety profile in ulcerative colitis. SPY001 achieved a 9.2-point RHI reduction, 40% clinical remi
